Therapeutic impact of orally administered cannabinoid oil extracts in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis
In Summary
A recent study has revealed the validity of treating multiple sclerosis (MS) and associated neuropathic pain (NNP) with medical cannabis. The therapeutic benefits of cannabis for MS and NNP was demonstrated by treating an experimental autoimmune encephalomyelitis animal model with cannabis which revealed an improved score on a neurological disability assessment and behavioral assessment. The authors describe this study as a critical step in advancing the literature describing the therapeutic effects of medical cannabis by validating the merit of such therapeutic effects.
Highlighted in this study is the importance of the ratio of cannabinoids when treating various ailments. The vast array of cannabinoids has a myriad of effects on the body depending on how which receptor of the endocannabinoid they act on, how they act on that receptor, and how they interact with other cannabinoids that were taken simultaneously. Cannabidiol (CBD) is frequently recommended to help minimize feelings of anxiety, whereas tetrahydrocannabinol (THC) can actually worsen anxiety at higher doses. When consuming cannabis a patient should always be careful to note the ratio and effect of each cannabinoid.
The study is available for review or download here
View more studies like this in the CED Foundation Archive
To explore related information, click the keywords below: